ADVERTISEMENT

Conference Report

Tirzepatide Cuts BP During Obesity Treatment

Mitchel Zoler   |   15 November 2022

CHICAGO – Treatment with the “twincretin” tirzepatide led to significant and potentially clinically meaningful cuts in 24-hour ambulatory blood pressure, compared with placebo, while causing modest increases in heart rate, in a prespecified substudy of the SURMOUNT-1 trial.

“The large effects on ambulatory 24-hour blood pressure raise the possibility that there may be important long-term...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right